A Phase 2 clinical trial of EVO301 in atopic dermatitis.
Latest Information Update: 06 Nov 2024
Price :
$35 *
At a glance
- Drugs APB-R3 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- 06 Nov 2024 New trial record
- 31 Oct 2024 According to Evommune Media Release, data from this study is expected in 2026.